October Drug Tariff News
The latest Category M adjustment (for October 2023) adds 10 items, bringing the total number of items in Category M to 661.
This adjustment reflects underlying market prices (between April – June 2023) and the result of the community pharmacy margin survey (latest result up until end of March 2023).
As well as the adjustments for market prices, medicine margin will be adjusted downwards by £21 million per quarter through Category M reimbursement prices.
The summary effect is that 161 lines are up in price, 14 by over 50 per cent and 473 prices are down in price, eight by over 50 per cent.
The new items are:
|Betamethasone valerate 0.1% cream||30g||£1.71|
|Betamethasone valerate 0.1% cream||100g||£3.54|
|Bimatoprost 300micrograms/ml / Timolol 5mg/ml eye drops||3ml||£4.08|
|Cabergoline 500microgram tablets||8||£17.69|
|Co-amilofruse 5mg/40mg tablets||28||£6.07|
|Dexamfetamine 5mg tablets||28||£14.80|
|Lorazepam 500microgram tablets||28||£19.48|
|Olopatadine 1mg/ml eye drops||5ml||£3.61|
|Promethazine hydrochloride 10mg tablets||56||£13.55|
|Pyridostigmine bromide 60mg tablets||200||£21.05|
Reference DDA website
Additions to Part 2
There have been 9 additions to Part 2 in the October Drug Tariff- ones which I think you may find of interest are:
Generally, items which fall into Part 2 of the Drug Tariff have no wholesaler discount, you are potentially dispensing at a loss. You may consider sending the prescription away to a local Pharmacy to be dispensed.
Additions to Part 8a
Only 3 items have been added to Part 8a of the October Drug Tariff, and these 3 are:
Deletions to Part 8a
6 items have been deleted from Part 8a of the October Drug Tariff- ones which I think you will find of interest are:
Items which have been removed from the Drug Tariff part 8A can still be prescribed and dispensed but you will need to endorse the prescription with manufacturer, pack size and price paid.
Other Changes to Part 8a
38 items are listed in ‘Other Changes, ones which you may find of interest are:
DDA would also like to remind everyone that Apixaban is now a Category M item and the reimbursement for both strengths has dropped significantly in the October Drug Tariff.